IGC Pharma

IGC Pharma FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of IGC Pharma (IGC) as of Nov 12, 2026 is 93.27 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 74.10 % — a change of 25.86% (higher).

FCF Conversion

93.27 %

YoY

25.86%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of IGC Pharma is 2026 93.27 % . FCF Conversion Rate (FCF/EBITDA) of IGC Pharma was 2025 74.10 % . It decreases by 25.86% higher compared to the previous year.

The IGC Pharma FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
82.74 USD
Jan 1, 2020
179.67 USD
Jan 1, 2021
140.64 USD
Jan 1, 2022
54.83 USD
Jan 1, 2023
66.63 USD
Jan 1, 2024
43.95 USD
Jan 1, 2025
74.10 USD
Jan 1, 2026
93.27 USD
The IGC Pharma FCF Conversion history
YEARFCF ConversionYoY
93.27 %+25.86%
74.10 %+68.60%
43.95 %-34.03%
66.63 %+21.52%
54.83 %-61.02%
140.64 %-21.72%
179.67 %+117.14%
82.74 %-30.67%
119.35 %+45.00%
82.31 %+725.80%
9.97 %-82.71%
57.65 %-0.44%
57.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IGC Pharma Stock analysis

What does IGC Pharma do? India Globalization Capital Inc. (IGC) is a Maryland-based company that focuses on the development, marketing, and sale of natural supplements, novel cannabis formulations, food and beverages, and the manufacturing of medical devices. IGC was established in 2005 and initially operated as a construction company in India. However, over the years, the company has evolved into a diversified company based in Maryland due to its innovative products and services. One of IGC's most well-known divisions is IGC Pharma, which focuses on cannabis-based medical formulations and medical devices. IGC holds patent applications for certain cannabis-based products and was one of the first companies to explore the use of cannabis as a potential treatment for Alzheimer's patients. In collaboration with the Institute for Medicine and the Origins of Infancy at the University of Maryland, IGC developed a novel THC-based medication for the treatment of spasms, pain, and other symptoms in multiple sclerosis patients. IGC has also developed the "Hyalolex" product, which is made from specific cannabinoids such as CBD. This preparation is available in Germany under the trade name "Cannabidiol Hexal." Hyalolex is available as a dietary supplement and has been proven effective in improving memory performance, attention, and cognitive abilities in Alzheimer's patients. IGC also operates the IGC Nutraceuticals division, which focuses on the manufacturing and marketing of high-quality natural products. These include vitamins, minerals, dietary supplements, and natural herbal supplements that promote physical and mental well-being and support healthy bodily processes. Some of IGC Nutraceuticals' products include Saffron for Depression Relief, the calcium and magnesium formulation, and Bharat Diagnostics. IGC will continue to invest in various fields, including cannabis-based pain relief, dementia treatments, electrochemical energy storage, and the manufacturing of devices that utilize natural resources such as coal and ore. Overall, IGC has become a diversified company that focuses on a variety of industries. IGC has been a pioneer in the cannabis industry and has gained a good reputation through innovative formulations and patents. By expanding into new industries and investing in new technologies, IGC will continue to stay at the forefront of innovation and strengthen its position as one of the emerging development companies in today's economy. IGC Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IGC Pharma stock

FCF Conversion Rate (FCF/EBITDA) of IGC Pharma is 93.27 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of IGC Pharma changed from 74.10 % to 93.27 %, representing a 25.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) IGC Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s IGC Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — IGC Pharma

All Key Metrics — IGC Pharma